Key Highlights

  • SkinBioTherapeutics plc (LSE:SBTX) gained 8.33% on 1 October 2026.
  • Interim CEO Rachel Parsonage and acting chair Alyson Levett have made their roles permanent.
  • Trading in the early months of the 2027 financial year is ahead of management's internal expectations.
  • Anita Slater joined as interim CFO in August, and talks on a new independent non-executive director are advanced.
  • The shares remain far below their 52-week high after a turbulent year that included a suspension and the CEO's departure.

SkinBioTherapeutics Shares Recover

SkinBioTherapeutics plc (LSE:SBTX) rose 8.33% on Thursday, 1 October 2026. The shares have been volatile since a pre-close trading update on 22 September, with very heavy volumes on 23 September. At around 6p, the stock sits close to its 52-week low and well below a high of about 23p, reflecting a difficult year for the company.

Why SkinBioTherapeutics Is in Focus

SkinBioTherapeutics is a Newcastle-based life science company focused on skin health. Its proprietary SkinBiotix platform originates from research at the University of Manchester. The company sells AxisBiotix food supplements targeting the gut-skin axis, aimed at conditions such as psoriasis, acne and eczema. These products are sold through Superdrug under an exclusive UK agreement, on Amazon and through other channels. The company also has a cosmetic skincare Business and has worked with Croda on commercialising its technology.

A Year of Upheaval

SkinBioTherapeutics (LSE:SBTX) has been through significant governance disruption in 2026. In February its chief executive Stuart Ashman resigned after being suspended pending an internal investigation into his conduct, and the board appointed an independent investigation. Rachel Parsonage became interim CEO in March. The shares were suspended on 1 April and restored to trading on 8 June. These events severely damaged confidence and drove the share price down sharply.

Stabilisation and Improving Trading

The 22 September update marked an attempt to draw a line under that period. The company confirmed that Rachel Parsonage and Alyson Levett would make their CEO and chair roles permanent. It also released a pre-close update for the year ended 30 June 2026 and said trading in the early months of the new financial year had been ahead of management's internal expectations. The board's immediate priorities are Revenue growth, reducing the underlying operating loss and preserving cash.

With Anita Slater appointed interim CFO in August and discussions about an additional independent non-executive director at an advanced stage, the company is rebuilding its Leadership team. The update came later than the mid-September timetable previously signalled, which drew criticism from some commentators, but the confirmation of permanent leadership offers a degree of stability.

Key Reasons Behind the 8.33% Gain

  • Leadership clarity: permanent CEO and chair appointments reduce uncertainty.
  • Trading ahead of plan: early FY27 performance is beating internal expectations.
  • Board rebuilding: new interim CFO and a further independent director in prospect.
  • Depressed valuation: shares near 52-week lows attract recovery buyers.
  • Consumer health growth: gut-skin supplements remain a fast-growing market segment.

Risks to Watch

SkinBioTherapeutics (LSE:SBTX) is still loss-making and burning cash. The company did not provide specific forward guidance in its latest update. Final FY26 figures remain subject to audit. Governance concerns from earlier in the year may take time to fade, and further funding could be required, potentially diluting shareholders.

What Comes Next

Investors will watch for audited FY26 results later in the year, the appointment of the new non-executive director, updates on retail partnerships such as Superdrug and evidence of a narrowing operating loss.